HLX14 (denosumab)

HLX14 Approval Pending

HLX14 (denosumab)

HLX14 Approval Pending

U.S. License Holder:

Organon / Shanghai Henlius Biotech

Date of License:

aBLA accepted by FDA October-2024

Last Update:

July-15-2025

approved_indications FDA-Approved Indications


HLX14 (denosumab) is not FDA-approved. An aBLA has been accepted by the FDA.

approved_indications U.S. Patent Litigations

PACER

Case No(s):

U.S. Patent Nos.
7,364,736 (Antibodies to OPGL) 7,888,101 (Host Cells Comprising Alpha 1, 2 Mannosidase and Culture Methods Thereof) 7,928,205 (Methods for Refolding of Recombinant Antibodies) 8,053,236 (Feed Media) 8,217,153 (Methods and Systems for Isolating Target Molecules from Complex Solutions by Column-Chromatography Using Wash Solutions Containing Organic Solvents) 8,460,896 (Host Cells and Culture Methods) 8,680,248 (Host Cells Comprising Alpha 1, 2 Mannosidase and Culture Methods Thereof) 9,228,168 (Feed Media) 9,359,435 (Methods for Modulating Mannose Content of Recombinant Proteins) 10,106,829 (Overexpression of n-glycosylation Pathway Regulators to Modulate Glycosylation of Recombinant Proteins) 10,227,627 (Overexpression of n-glycosylation Pathway Regulators to Modulate Glycosylation of Recombinant Proteins) 10,513,723 (Decreasing Ornithine Production to Decrease High Mannose Glycoform Content of Recombinant Proteins) 10,583,397 (Process Control Systems and Methods for Use with Filters and Filtration Processes) 10,655,156 (Overexpression of N-glycosylation Pathway Regulators to Modulate Glycosylation of Recombinant Proteins) 10,894,972 (Methods for Increasing Mannose Content of Recombinant Proteins) 11,077,404 (Process Control Systems and Methods for Use with Filters and Filtration Processes) 11,098,079 (Charged Depth Filtration of Antigen-Binding Proteins) 11,192,919 (Removal of Leaked Affinity Purification Ligand) 11,254,963 (Increasing Ornithine Accumulation to Increase High Mannose Glycoform Content of Recombinant Proteins) 11,319,568 (Methods for Increasing Mannose Content of Recombinant Proteins) 11,434,514 (Methods for Increasing Mannose Content of Recombinant Proteins) 11,459,595 (Methods for Increasing Mannose Content of Recombinant Proteins) 11,492,372 (Removal of Leaked Affinity Purification Ligand) 11,946,085 (Methods for Increasing Mannose Content of Recombinant Proteins) 11,952,605 (Methods for Increasing Mannose Content of Recombinant Proteins) 12,084,686 (Antibodies with Modulated Glycan Profiles)

Plaintiffs
Amgen Inc.; Amgen Manufacturing Limited

Defendants
Shanghai Henlius Biotech, Inc.; Shanghai Henlius Biologics Co. Ltd.; Organon & Co.; Organon LLC

Status
Case Ongoing

BPCIA
Y

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha